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ABSTRACT 
 
 
 
In response to a viral antigen, the immune system produces epitope-specific T-
cells. The majority become cytotoxic T-cells that clear the virus, while a small population 
remains in memory form to protect against future infections. To determine if multiple, 
simultaneous infections compromise this protection, mice were immunized with either a 
single or combination of viruses, then immuno-protection levels were analyzed after a 
single virus rechallenge by viral titer, viral epitope frequency, and animal weight loss. 
The results indicate that when immunized against the rechallenge virus, either alone or 
with another virus, mice receive sufficient protection at day 5. Weight analysis, however, 
shows that the protection may be dependent upon the viruses used for vaccinations and 
rechallenge infections.  
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BACKGROUND 
 
 
To understand how simultaneous and individual 
vaccinations affect the immune responses of mice, a solid 
understanding of the T-cell adaptive immune system is 
required.  Specifically, development and activation of memory 
CD8 T-cells by viral peptides is the main determinant of the 
protection provided by the vaccinations. To further explain the 
results of this MQP, the infection pathways of two viruses, 
Lymphocytic Choriomeningitis Virus (LCMV) and Pichinde 
Virus (PV) will also be explained. 
 
T-Cells 
 Upon encountering a foreign antigen, naïve T-cells 
differentiate and proliferate into cytoxic effector T-cells (Figure 
1). These effector T-cells are cytokine-producing cells that act 
to clear the foreign antigen from the body. Once the foreign 
antigen is cleared, these cells are no longer needed, and 
decrease in number by apoptosis. Some of these cells, however, 
remain in the periphery of the body in memory form (Kaech 
and Ahmed, 2001).  Memory T-cells require less interaction 
with antigen to become re-activated, as compared to naïve cells, 
Figure 1. Development of CD8 
T-Cells.  Figure from Janeway, 
2005-Fig. 10.34). 
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and are thus able to quickly provide protection against future infections, or to clear 
existing persistent infections (Selin and Welsh, 1997).  
 The memory T-cells exist in a repertoire made up of a set number of cells. This 
limitation forces a preferential hierarchy of epitope specific memory T-cells. Upon each 
new infection the frequencies of these cells changes. As an evolving environment, the 
memory T-cells that are cross-reactive with a second pathogen are conserved, while non-
cross-reactive T-cells are lost (Selin and Welsh, 2004).  
 
Degeneracy of T-Cell Recognition 
 Upon initial viral infection, the virus enters the host’s cells and can follow several 
different pathways depending on the virus, environmental factors, and host cell type.  The 
mostly common pathway is when a virus utilizes the organelles of a host cell for 
replication. During this process, some of the produced viral proteins are broken down and 
presented on the surface of the cell by MHC class I molecules (Figure 2). This 
presentation then identifies the cell as infected with non-self antigen; normal, self-
proteins of the cell also undergo this same presentation process, but T-cells active against 
self-antigens are eliminated (Janeway, 2005). 
 
 
 
Figure 2. MHC Presentation of Viral Peptides 
(Janeway, 2005- Fig. 1.28). 
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These small presented proteins are recognized by antigen presenting cells (APC’s), such 
as dendritic cells, whose main function is to activate the naïve T-cells that have the 
appropriate T-cell receptor. T-cell receptor (TCR) recognition of viral antigen is limited 
to 8-10 amino acid length peptides. These peptides or epitopes are presented in MHC 
class I molecules on the surface of infected cells or APC’s (Falk et al, 1991) (Figure 3).  
 
The interactions of TCR’s with epitopes, located in a MHC class I molecules, 
occur through the side chains of only a few amino acids, therefore changes in the 
remaining viral amino acid sequence would not have a great impact on the recognition 
(Bjorkman, 1997).  
 
Cross-reactivity 
 Cross-reactive T-cells have the ability to recognize multiple epitopes.  For 
example, in some cases of Chlamydia infection, antibodies induced against Chlamydial 
surface proteins also cross-react with heart muscle proteins to induce inflammation.  In 
this process, TCRs recognize antigen that they were not originally primed against, but kill 
the cells in a similar manner. There are multiple explanations for this occurrence (Figure 
4). Molecular mimicry is a mechanism in which one protein induces an immune response 
against a similar protein. Another mechanism, known as alternative recognition, suggests 
Figure 3. Structure of the binding 
site of a MHC class I molecule  
for foreign proteins (Janeway, 
2005- Fig. 3.23). 
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that antigens may bind to different places on the TCR (Daniel et al, 1998).  T-cells may 
also have two different TCRs, which have highly variable recognition abilities (Alam and 
Gascoigne, 1998).  
 
 Cross-reactivity has been found to occur commonly between related pathogens, 
but can also occur between unrelated ones. Calculations predict that a single TCR has the 
ability to recognize 106 different 9-amino acid epitopes (Mason, 1998). When taken 
together, the highly evolving T-cell memory pool and the cross reactivity of TCRs makes 
the immune system capable for protecting against a wide range of pathogens.  In theory, 
after multiple viral challenges the T-cell memory pool will be composed of highly 
effective cross-reactive T-cells, which would provide at least partial protection against 
the majority of pathogens.          
 
 
Epitope Hierarchy 
Figure 4. Possible Mechanisms of T- 
cell cross-reactivity. Interactions of 
TCRs with peptides in MHC class I 
molecules.  
Top- left- Peptide interaction with an 
appropriate TCR. 
Top-middle-Same TCR of left 
interacting with a second peptide 
through the same amino acids 
(molecular mimicry). 
Top-right- Same TCR interacting with a 
third peptide through different amino 
acid side chains. (alternative 
recognition) 
Bottom- Two different TCRs on a single 
T-cell allowing it to interact with 
multiple peptides.  
(Welsh and Selin, 2002) 
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 Another influence on the frequency of memory T-cells is the variety of viral 
specific epitopes. Each virus has multiple epitopes to which the immune system responds. 
These resulting epitope specific T-cells will persist in memory for the life of the subject. 
Experiments have shown that in naïve mice infected with a single virus, the epitope 
hierarchy is very predictable (Chen et al, 2000).  The LCMV virus for example produces 
GP33, NP396 and GP276 immunodomiant epitopes, which have the strongest responses 
appearing in the greatest number during both acute and memory phases. There are also 
several other subdominant or weaker epitopes such as GP92, GP118, and NP205.   The 
Pichinde virus has far fewer epitopes, two are immunodominat (NP38 and NP122), and 
one subdominant (NP205) (Table 1).   
  
 
 
 
 
The nomenclature for the epitopes has to do with the type of protein and its 
location in the genome.  As seen in Table 1 the two types of epitopes are NP and GP.  NP 
is a nucleocapsid protein, which often coats the viral genome, while GP is a glycoprotein 
often found at the viral surface. The number that follows is the nucleotide at which the 
protein starts.  
 The dominance of an epitope is affected by several factors. The ability of infected 
cells and APCs to process and present the epitope affects its dominance.  The affinity of 
the viral peptide to both the MHC molecule and the TCR also affects the rate at which the 
Virus 
Epitopes 
 
 Dominant Subdominant 
LCMV GP 33 GP 92 
 NP 396 GP 118 
 GP 276 NP 205* 
PV NP 38 NP 205* 
 NP 122  
Table 1. Viral Epitopes for 
LCMV and PV. 
* cross-reactive epitopes 
between LCMV and PV 
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naïve T-cells are primed to this epitope (Yewdell and Bennink, 1999). The faster the 
epitope specific T-cells are activated the greater the frequency of them. 
 The LCMV epitope NP205 is cross-reactive with PV NP205.  These two proteins 
share 6 out of 8 amino acids at this locus. The normally subdominant NP205 epitope can 
become dominant when these viruses are given in sequence (i.e. an LCMV-immune 
mouse rechallenged with PV, or a PV-immune mouse rechallenged with LCMV).   This 
cross-reactivity can produce immunoprotection that can save a mouse from a lethal dose 
of the second virus (Brehm et al, 2002).  
 
Immunopathology 
 Along with partial protection, immunopathology can also develop in response to 
the proliferation of cross-reactive T-cells (Doherty and Zinkernagel, 1974).  At the peak 
of an infection, cytotoxic T-cells lyse infected cells and produce inflammatory cytokines. 
When the virus is cleared quickly by memory T-cells, there is limited cell lysis and 
minimal immunopathology.  If the memory T-cells formed from the first viral infection 
are only slightly cross-reactive with the new second virus, there will only be slight 
protection, and thus slower viral clearance.  Also due to the competition of cells within 
the immune system, this cross-reactive response, although weak, may inhibit a better 
response produced from naïve T-cells (Hemmer et al, 1998).   
 This heterologous immunity produced by cross-reactive T-cells provides a new 
explanation of the different responses between individuals exposed to the same virus. An 
individual’s immune system is a pool of memory cells that reflects that individual’s 
previous infections.  Immunity is most effective when the memory T-cell repertoire is 
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composed of cross-reactive T-cells that have the ability to quickly clear a viral infection. 
Each individual has a unique pool of memory cells, which have an unpredictable 
protection level. 
 
Cytokines and Surface Receptors 
 As cells differentiate the receptors on their surface and the cytokines they release 
change. The two main surface receptors that were analyzed in this MQP were CD8 and 
CD44.  CD8 is a protein marker on the cell surface of CD8 cytotoxic T-cells, as opposed 
to CD4 helper T-cells. CD4 helper T-cells are responsible for recognizing MHC class II 
molecules presentation of epitopes as compared to CD8 cytotoxic T-cells that recognize 
the MHC class I molecules presentation of viral epitopes. CD44 is a cell adhesion 
molecule that is present on the surface of naïve T-cells, but only at low levels. After 
stimulation, this receptor increases in frequency and remains on the surface of memory 
cells to help with cell-to-cell interactions.   
 The two cytokines that were used in this MQP were interferon gamma (IFN-
gamma) and tumor necrosis factor alpha (TNF-alpha). The majority of interferons are 
involved with the innate immune response to viral infections. IFN-gamma, however, is 
released by T-cells in response to stimulation. TNF-alpha plays a similar role as IFN-
gamma. In mice that are depleted of these two cytokines death will ensue a few days after 
a viral infection (Janeway, 2005).  
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Murine Arenaviruses Used in This Project 
 The two murine viruses used in this MQP were LCMV (Lymphocytic 
Choriomeningitis Virus) and PV (Pichinde Virus) which are both members of the 
Arenaviridae family. This family has been found to form chronic infections in rodents 
across Europe, Africa and the Americas.  LCMV is an Old World arenavirus while PV is 
a member of the New World arenavirus group.  However, the relationship between the 
two viruses is very limited as shown by their minimal cross-reactivity (NP205 has been 
found to be highly conserved between all Old and New World arenaviruses) (Buchmeir, 
2001).  Neither of these viruses are cytolytic. The majority of the damage is produced by 
the immune systems of the mice.   
 LCMV (Figure 5 & 6) was the first arenavirus to be isolated in 1933.  It is 
understandably, one of the most widely understood viruses in murine models. As this 
virus invades the cells of mice, there is a balance between protection and damage with the 
proliferation of T-cells (Buchmeir, 2001).  
 
  
 
 
 
 
 
Figure 5.  Electron Microscopy of LCMV.  A. virons 
budding from infected BHK-21 cells. B-D. Purified LCMV 
virons with surface glycoproteins visible. Bar indicates 
100nm. 
Micrography from studies by M.B.A. Oldstone, Peter W. 
Lambert, and Michael Buchmeier. 
 http://www.scripps.edu/newsandviews/e_20021028/print-
oldstone.html 
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Pichinde virus (Figure 6) is not as aggressive as LCMV, and is given at much 
higher doses (an increase of ~2.5 logs) to get a response that is easily detectable. It also 
produces much fewer epitopes compared to LCMV.   
 
Two strains of LCMV were used in this MQP: Armstrong and Clone 13 (cl 13).  
These two strains differ in only two amino acids, but cl 13 is found to cause a much 
stronger infection (Ahemd et al, 1984).  LCMV Armstrong was used to immunize all of 
the mice, which received LCMV.  LCMV cl 13 was used as the secondary, rechallenge 
virus because it is a more aggressive strain known to cause persistent infections at the 
given dose. To add to the evidence of immunopathology of viral infections, mice given a 
high dose of LCMV cl 13 (10X higher than dose used in this MQP), which induces clonal 
exhaustion, will live longer and show less weight loss than mice given a persistent 
infection dose (dose used in this MQP) (Cornberg, unpublished).  
 Another element of LCMV that makes it more complicated than PV is the 
induction of a neutralizing antibody. This antibody is produced by the subject to help 
combat the infection. When this antibody is transferred into a mouse, it is found to 
protect against a lethal dose of LCMV (Webster and Kirk, 1974). 
 
Fig. 6. Image Analysis of Pichinde and LCMV Arenaviruses.  
The arenavirus glycoprotein complexes are present in 2-
dimensional, orthorhombic arrays on the surface of the virion. 
Images of New World Pichinde (top row) and Old World 
lymphocytic choriomeningitis virus (bottom row) are shown.  
Scale bar = 50 Å.  
http://www.scripps.edu/news/sr/sr2004/np04buchmeier.html 
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PROJECT PURPOSE 
Memory T-cells that exist in individuals perviously infected with a virus (or who 
have received a vaccination for a virus) will provide immunoprotection to future 
infections with the same virus or other pathogens presenting similar proteins. When these 
memory cells are only partially cross-reactive with the secondary infection, immuno-
pathology may also develop.  
 The Selin Lab has done several experiments looking at the evolution of the 
memory T-cell repertoire in mice after several infections with a variety of viruses. These 
experiments show changes in viral epitope hierarchies are unpredictable in a sense that 
cross-reactive epitopes are not known until the two given viruses are used to infect mice 
in a series of experiments, which examine the protection and T-cell responses. This 
protection has also been found to be dependent on the order of the infections. If virus A 
was given to a virus B-immune mouse the protection by cross-reactive T-cells may be 
different than if virus B was given to a virus A-immune mouse.  
 This MQP focuses on a slightly different aspect of viral immunoprotection. It 
assesses the protection to a single virus, by the memory T-cells acquired from either 
simultaneous or individual vaccinations. It examines the ability and limits of the immune 
system to produce T-cells when exposed to multiple viruses at the same time. The extent 
of the defense provided by these activated memory T-cells is analyzed in terms of viral 
titer, viral epitope frequency, and animal weight change. Another strong influence on the 
applications of simultaneous vaccinations is the possibility of immunopathology due to 
T-cell proliferation.  
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The conclusions from the MQP could be applied to the administration of vaccines 
to humans. If mice can be effectively immunized with two viruses simultaneously then 
perhaps humans can be also. This also raises questions to how many vaccines can be 
given simultaneously and the development of immunopathology.  
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MATERIALS AND METHODS 
 
 
Experimental Design  
  
Mice were given a primary infection of one (LCMV or PV), both (LCMV + PV) 
or none (Naïve) of the viruses. Mice were allowed to develop immune responses to the 
primary infections. At approximately 6 weeks post-primary infection their memory T-cell 
responses were analyzed by an intracellular cytokine assay using blood taken from the 
tails of the mice (Figure 7).  
 
 
 
 
 
 
 
 
Naive  
 
 
 
LCMV  
 
 
 
PV 
 
 
 
LCMV + PV 
 
 
Day 0 
Day 4/5: 
ICS and 
Plaque 
assay 
Rechallenge 
infection*  
~6 weeks 
post-primary 
infection 
Tail Bleeds 
(ICS) 
Primary 
Infection 
* Mice were weighed 
Day 0 – Day 4/5 
Figure 7. Experiment Outline 
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Mice were then rechallenged with a secondary infection of either LCMV or PV. 
At four or five days post-rechallenge (two out of the three PV rechallenge experiments 
were harvested at day 4 post rechallenge) the mice were harvested using ½ spleen for 
another intracellular cytokine assay while the remaining ½ spleen, liver, and fatpads were 
taken for a plaque assay to determine viral titer. For each virus (LCMV and PV) three 
experiments were performed. Within each experiment there were four groups (naïve, 
LCMV, PV, and LCMV + PV). Each group contained five mice (Figure 7).  
 
IP/IV Injections 
The mice used for these experiments were all male C57BL/6J at least 6 weeks of 
age.  Mice were given LCMV Armstrong IP at 5X104 pfu per mouse and PV at 2x107 pfu 
per mouse for primary infections. Mice were allowed to clear the viruses (6 weeks) and 
then rechallenged. Secondary infections were LCMV cl 13 at 2x105 pfu per mouse and 
PV at the same dosage as the primary infection. For IP (intraperitoneal) injections, mice 
were given 100 µl of virus. Cl 13 was diluted into Hanks basic salt solution and each 
mouse received 200 µl IV (intravenous) into the tail vein.  
 
Plaque Assays 
Plaque assays were used to determine viral titer in various tissues. Fatpads, livers, 
and ½ spleens were ground, triple aliquoted at 300 µl per tube and frozen at -80˚C. Vero 
cells were used at 60-70% confluency at 1.5 X10^5 cells per well in 6 well plates. For 
fatpads and spleens 1:10 serial dilutions were made from 0-5.  Livers were extended to 
six dilutions due to the high enzymatic activity of this organ. 100 µl of sample for each 
dilution was added to the well and allowed to incubate at 37˚C for 1.5 hours (rocked at 45 
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min). Plates were overlayed with 4 ml of 1:1 ratio of EMEM and 1% agarose. Neutral red 
stain was used for both viruses. PV plates were stained on day 3 and read at days 4 and 5. 
LCMV was stained on day 4 and read at days 5 and 6.   
 
Intracellular Cytokine Assays (ICS) 
Intracellular cytokine assays were used to determine viral epitope hierarchy and 
cytokine production. In this MQP, intracellular cytokine assays were preformed with both 
blood samples and ½ spleens. 
 Six weeks after the primary infection approximately 400ul of blood was taken 
from the tails of each mouse, except the naïve groups. Blood cells were lysed and 
resuspended in RPMI media. Due to the low frequency of lymphocytes in blood only five 
stimulations were done for each mouse: negative control, GP33, LCMV-NP205, NP396 
and NP38. Cells were stained for CD44 (FitC), CD8 (PerCP Cy 5.5), IFN-gamma (APC), 
and TNF-alpha (PE).  
The remaining half of the spleen from the day 4/5 post-rechallenge harvest was 
ground, cells were counted with tryphan blue, and placed in a 96 well plate at 2x107 cells 
per well. Naïve ½ spleens were pooled in each experiment, but all others were kept 
separate. For each mouse the splenocytes were stimulated with: no stim (negative 
control), anti-CD3 (positive control), GP33, GP92, GP118, LCMV-NP205, GP276, 
NP396, NP38, NP122, and PV-NP205. Splenocytes were allowed to incubate with 
peptides for 5 hours at 37˚C. This allows for the production of cytokines from the 
stimulated T-cells. Cells were then stained for surface receptors: CD44 (FitC) and CD8 
(PerCP Cy5.5) and for cytokines: TNF-alpha (PE) and IFN-gamma (PE Cy7).  
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For both cell types samples were then read by the FACS machine and analyzed in 
FloJo. Cells were selected by a series of gating: live cells, CD8+ and then analyzed by 
IFN-gamma vs. TNF-alpha for total IFN-gamma production.   
 
Weight Analysis 
Mice were weighed from day 0 to day 4/5 post rechallenge infection at 
approximately the same time each day. Analysis was determined by percentage of weight 
change.  
 20 
RESULTS 
 
This MQP compares the immunoprotection provided by either simultaneous or 
individual vaccinations in response to a rechallenge infection of a single virus.  The 
protection from the vaccines was determined by pre-rechallenge memory T-cell 
frequencies and viral titer, weight change analysis, and post-rechallenge T-cell 
frequencies. There is one set of results presented for each of these areas on each of the 
experiments (Figure 8).  
 
 
Pre-rechallenge Memory T-cell Frequencies 
 
 In order to determine the frequencies and hierarchies of the memory T-cells for 
the mice in each group (Naïve, LCMV-immune, PV-immune, LCMV + PV-immune) 
before the rechallenge infections, intracellular cytokine assays were performed on T-cells 
isolated from blood samples (Figure 9). From these results, it was determined that all 
groups of mice in both experiments had protection against the virus to which they were 
immunized. 
Since both of these rechallenge groups received the same vaccinations they 
should have similar memory T-cell profiles. LCMV-immune mice had high levels of 
Figure 8. Experimental 
Design.  
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GP33 and NP396 specific CD8 T-cells as expected due to their immunodominance with a 
low frequency of the subdominant NP205 specific CD8 T-cells. The PV-immune mice 
showed dominant levels of the NP38 specific response in both experiments. 
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Individually, LCMV + PV-immune mice had high levels of variability and 
prioritized the dominant epitopes for either of the viruses. This variability between 
individual mice was also seen in the differences between the two experiments. The 
responses were much lower in the LCMV + PV-immune group of the PV rechallenge as 
Figure 9. Percentages of 
cells producing IFN-
gamma (memory cells) 
for LCMV and PV 
specific epitopes.  
Mice rechallenged with 
LCMV (top) and PV 
(bottom).  Y-axis shows 
Percentage of cells 
producing IFN-gamma. 
Data presented as a mean 
of 10 mice +/- SEM.  
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compared to the LCMV rechallenge. This could potentially affect the immunoprotection 
that these mice developed.  
 
Viral Titers 
 
The viral titers of the mice were determined on day 4/5 post-rechallenge by 
plaque assay of spleens, livers, and fatpads (Figure 10).  
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Figure 10. Viral Titers 
determined by plaque 
assay of ½ spleens, 
fatpads, and livers.  
Mice rechallenged by 
LCMV (top) and PV 
(bottom).  
Data is presented as a 
mean of 10 mice +/- 
SEM.  
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The different viral titers are indicators of both immunoprotection, but also the 
time course of the virus. Naïve mice rechallenged with LCMV cl 13 will usually die at 
day 12 post-infection while by day 8 of a PV infection the virus has been cleared. This 
was depicted in both of these experiments by the large difference in viral titers. The naïve 
mice of the PV rechallenge experiment had an approximate 99% inhibition compared to 
the naïve mice of the LCMV rechallenge experiment. 
In the LCMV rechallenge experiment, (Figure 10 upper panel) PV-immune and 
naïve mice had much higher viral titers than LCMV-immune or LCMV + PV-immune 
mice. PV-immune mice had a slight decrease in viral titer in spleen and fatpads as 
compared to the naïve mice. This may be due to the cross-reactive T-cell response. The 
LCMV-immune and LCMV+PV-immune groups were expected to have 
immunoprotection to the virus due to their memory T-cells specific for this virus. This 
was proven by the similar pattern of low titers of LCMV in all these organs at day 5 post-
rechallenge (<1 log pfu/ml).  
When rechallenged with PV (Figure 10 lower panel) viral titers are significantly 
lower is all groups. Naïve mice showed the highest concentrations of virus in fatpads, 
which is characteristic of this virus. The cross-reactive T-cell responses between LCMV 
and PV provided partial protection for the LCMV-immune group, which showed over 
90% inhibition compared to naïve animals. PV-immune mice had undetectable virus 
while LCMV + PV-immune mice had slight amounts virus detectable in only a few 
individuals. Upon statistical analysis, however, this difference is not significant (p=0.1).  
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Weight Loss 
The percentage of weight change in the mice was calculated after the rechallenge 
infection (Figure 11). Weight change in mice infected with these viruses is comparable to 
symptoms that develop in humans and other large mammals.   
Similar to the viral titers, the weight change curves for the two experiments are 
slightly different due to the differences between the viruses. When rechallenged with 
LCMV cl 13 (Figure 11 upper panel) the naïve and PV-immune mice lost the most 
weight the fastest after infection. After day 3, however, the PV-immune mice rebounded 
while the naïve mice continued to lose weight. This rebounding effect could be due to the 
cross-reactive T-cell responses between the two viruses and correlates with the viral titer 
results. LCMV-immune and LCMV + PV-immune mice lost far less weight and both had 
regained their weight by day 5. LCMV-immune mice, however, dropped ~2% by day 1 
post rechallenge while the LCMV + PV-immune mice took longer to lose weight and 
only lost ~1%.  These findings indicate that even though these two groups had similar 
weights and viral titers at day 5, LCMV + PV-immune mice has less severe symptoms. 
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Figure 11. 
Percentage weight 
loss of mice 
rechallenged with 
LCMV (top) and PV 
(bottom).  
Data is presented as 
a mean of 10 mice.  
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PV RECHALLENGE: AVERAGE WEIGHT CHANGE
92
93
94
95
96
97
98
99
100
101
102
0 0.5 1 1.5 2 2.5 3 3.5 4 4.5
days post rechallenge
p
e
rc
e
n
ta
g
e
 w
e
ig
h
t 
c
h
a
n
g
e
NAÏVE
LCMV
PV
LCMV + PV
 
The weight results from the PV rechallenge experiment (Figure 11 lower panel) 
provided a different conclusion. The naïve and LCMV-immune mice showed a similar 
dramatic loss of weight soon after rechallenge. Naïve mice, however, rebounded ~1% at 
day 4 while the LCMV-immune remained low. These weight losses showed little 
correlation with the viral titers. The weight curves for the PV-immune and LCMV + PV-
immune mice showed a similar trend until day 4. Both groups took longer to lose the 
weight than LCMV-immune or naïve mice. This showed immunoprotection to the 
rechallenge. At day 4, LCMV + PV-immune mice continued to drop to their weight 
levels similar to LCMV-immune mice while PV-immune mice rebounded. The LCMV 
immunity of the LCMV and LCMV + PV-immune groups seems to be the downfall of 
these mice. Immunopathology, in the form of increased weight loss, was mediated by the 
immune response. It is possible that the cross-reactive T-cell responses in LCMV-
immune mice are being actively recruited to sites of infection resulting in symptoms, but 
are not very efficient at clearing the virus.   
 
 26 
Post-Rechallenge Memory T-cell Frequencies 
After the rechallenge infections, a second intracellular cytokine assay was 
performed on the spleens from the individual animals (naïve pooled) (Figure 12). 
Changes in viral epitope hierarchy from before rechallenge were identified.  
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Figure 12. Percentages of cells producing IFN-gamma for LCMV and PV specific epitopes (right) 
and positive and negative controls (left).  
Mice rechallenged with LCMV (top) and PV (bottom).  
Data presented as a mean of 10 mice +/- SEM.  
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The intracellular cytokine assay (ICS) showed the specific viral epitopes used by 
the immune system of the mouse to respond to the virus. When vaccinated mice had 
memory cells that were either cross-reactive or specific for the rechallenge virus, their 
frequency in the mouse increased due to their efficiency in clearing the virus. 
In the LCMV rechallenge experiment (Figure 12 upper panel), the naïve mice had 
low total IFN-۟γ levels induced by all specific viral epitopes, with the exception of GP33 
(left side of the figure). This may be a developing response, but day 5 may be too early to 
see the full proliferation of the T-cells. PV-immune mice show significantly high levels 
of NP205 (both LCMV and PV). These are cross-reactive memory T-cells that are being 
activated and used to clear the virus. Like the naïve mice, the PV-immune mice are 
developing a GP33 response showing that the cross-reactivity is not enough to combat 
LCMV cl 13. The LCMV-immune mice show normal levels of all dominant LCMV 
epitopes (GP33, GP276 and NP396). The LCMV + PV-immune mice have LCMV 
epitope frequencies comparable to the LCMV-immune mice. Thus, the dominant LCMV 
epitopes are activated as the immune system attempts to clear the virus.   
When rechallenged with PV (Figure 12 lower panel) there much lower levels of 
T-cell proliferation at day 4 as compared to the LCMV rechallenge experiment at day 5. 
LCMV-immune mice have low frequencies of viral specific memory T-cells, but show 
only a slight increase in NP205 cross-reactive epitope. From previous experiments, there 
was a greater expected increase in NP205 specific memory T-cells, however, a greater 
proliferation may be seen at later time points.  PV-immune mice showed a significant 
increase in the PV epitopes, NP38 and NP122. When mice are vaccinated against both 
LCMV + PV the PV specific epitopes proliferate in response to a PV rechallenge. T-cells 
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specific for the LCMV epitopes were detected at low, memory-like frequencies in the 
maintained hierarchy. 
Applying these results to human vaccine administration would show that multiple 
vaccines can be given to an individual at a single time and they will develop sufficient 
protection to future infections. As seen with the differences between LCMV and PV there 
may be cases in which immunopathology will develop due to low efficiency of cross-
reactive memory T-cells. Here lies a major difference between murine models and 
humans that makes definitive conclusions much harder: humans are constantly being 
exposed to pathogens while experimental mice are kept in sterile conditions. There is no 
way to predict the memory T-cells of a specific individual in order to determine if any 
cross-reactivity will occur. Due to the high potential for TCR recognition cross-reactivity 
is expected to exists. In this MQP cross-reactivity occurred and the results showed that 
protection was produced; vaccination will therefore still have an effect in the case of 
unpredictable cross-reactivity.  
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DISCUSSION 
 
Due to the presence of viral specific memory T-cells in mice that received either 
simultaneous or individual vaccines, they had sufficient immunoprotection at day 4/5 to 
clear a post-rechallenge infection. With similar T-cell frequencies and viral titers in 
singly and multiply infected mice at this time point, it seems as though the effect of 
receiving multiple vaccines at the same time is minimal. Evidence from the weight 
change analysis, however, leaves several questions about the efficiency at which the virus 
was cleared in the simultaneously vaccinated mice compared to the individually 
vaccinated mice. To access these questions further experiments should be performed at 
earlier and later time points.  
 
LCMV Rechallenge 
 
 This experimental group tested the rechallenge of the mice with a stronger, more 
lethal virus, LCMV cl 13. Weight analysis showed that early after rechallenge the 
simultaneously immunized mice maintained their weight more than any other group 
(Figure 11). The correlation between T-cell proliferation and weight change would 
suggest that the T-cells that these mice produced a high affinity for LCMV and cleared 
the virus well, or that the LCMV neutralizing antibody was assisting the clearing of virus. 
By day 5, the T-cell frequencies of the LCMV-immune and LCMV + PV-immune mice 
were equal so determining if any specific epitopes were used to clear virus early in 
infection is not possible with these results. Experiments using earlier time points, 
however, would provide this information. 
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PV Rechallenge 
  The results for this experiment vary greatly from the LCMV rechallenge 
experiment. LCMV and PV, however, are only distantly related so their infection time 
courses are understandably different. The pre-rechallenge T-cell frequencies of the PV 
rechallenge experiment were slightly lower than expected from the results of the LCMV 
rechallenge experiment. This could be due to several factors. All of the mice for both 
experiments had the same date of birth and were immunized on the same day, but were 
bled or rechallenged on the different days. This may have introduced unknown variables, 
however, replication and duplication were performed in both cases. This may also just be 
an another indicator of the wide variability in the LCMV+PV-immune memory cell 
repertoires.    
The weight loss for this experiment was similar to that of the LCMV experiment 
in the fact that the two groups that were not immunized against the rechallenge virus lost 
the most weight the fastest, but by day 4 there were different results. The two groups that 
had LCMV memory T-cells had the lowest weights and did not show any weight regain 
(Figure 11). In terms of viral titer, the naïve mice had the highest titer levels followed by 
LCMV-immune mice approximately 90% inhibition (Figure 10). Of the few LCMV + 
PV-immune mice that had not cleared the virus by day 4, there were very low viral titers 
showing that they were indeed clearing the virus even though they were losing weight. 
The weight change in LCMV-immune and LCMV + PV-immune mice can be explained 
by the stimulation of NP205 cross-reactive memory CD8 T-cells that have little 
efficiency in clearing virus (Figure 12).  
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In conclusion the results show a trend of sufficient immunoprotection in all mice 
that have received a vaccination to the rechallenge virus, be it individually or in 
conjunction with a second vaccination. Weight analysis identified distinct differences in 
the rate of weight change, or T-cell proliferation, in the different groups soon after the 
second infection in both experiments. These differences may prove to show different 
immunopathological developments from these viruses.  
 
 32 
BIBLIOGRAPHY 
Ahmed, R. et al. 1984. Selection of genetic variants of lymphocytic choriomeningitis 
virus in spleens of persistently infected mice: role in suppression of cytotoxic T 
lymphocyte response and viral persistence.  J. Exp. Med. 160: 521-540.  
 
Alam, S.M and Gascoigne, N.R. 1998. Posttranslational regulation of TCR V-alpha 
allelic exclusion during T-cell differentiation.  J. Immunol. 160: 3883-3890.  
 
Bjorkman, P.J. 1997. MHC restriction in three dimension: a view of T-cell 
receptor/ligand interactions. Cell 88: 167-170.  
 
Brehm, M.A. et al. 2002. T-cell immunodominance and maintenance of memory 
regulated by unexpectedly cross-reactive pathogens.  Nat. Immunol. 3: 627-634. 
 
Buchmeier, M. 2001. Arenaviridae: The Virus and Their Replication. In Field’s Virology, 
Knipe, ed. Philadelphia: Lippincott Williams & Wilkins. Pg.1635-1662. 
 
Chen, W. et al. 2000. Dissecting the multifactorial causes of immunodominace in class I-
restricted T-cell responses to viruses.  Immunity. 12: 83-93.  
 
Cornberg, M. Unpublished.   
 
Daniel, C. et al. 1998. A basis for alloreactivity: MHC helical residues broaden peptide 
recognition by the TCR.  Immunity  8: 543-552. 
 
Dohery, P.C. and Zinkernagel, R.M. 1974. T-cell mediated immunopathology in viral 
infections. Transplant. Rev. 19: 89-120. 
 
Falk, K. et al. 1991. Allele-specific motifs revealed by sequencing of self-peptides eluted 
from MHC molecules. Nature 351: 290-296.  
 
Hemmer, B. et al. 1998. Relationships among TCR ligand potency, thresholds for 
effector function elicitation, and the quality of early signaling events in humans T-cells. 
J. Immnol. 160: 5807-5814. 
 
Janeway, C., Travers, P., Walport, M., Shlomchik, M. 2005. Immunobiology: the 
immune system in health and disease.  New York: Garland Science Publishing.  
 
 Kaech, S.M. and Ahmed, R. 2001. Memory CD8+ T-cell differentiation: initial antigen 
encounter triggers a developmental program in naïve cells.  Nat. Immunol. 2: 415-422. 
 
Mason, D. 1998. A very high level of cross-reactivity is an essential feature of the T-cell 
repertoire. Immunol. Today 19: 395-404. 
 
 33 
Profile: C57BL/6J. 1989. The Jackson Laboratory. Retrieved on April 2, 2006 from: 
<http://jaxmice.jax.org/library/notes/438b.html> 
 
Selin, L.K. and Welsh, R.M. 1997. Cytolytically active memory CTL present in 
lymphocytic choriomeningitis virus  (LCMV)-immune mice after clearance of virus 
infection. J. Immunol. 158: 5366-5373. 
 
Selin, L.K. and Welsh, R.M. 2004. Plasticity of T-cell memory responses to viruses. 
Immunity 20: 5-16.  
 
Webster, J.M. and Kirk, B.E. 1974. Neutralizing antibody response of guinea pigs to 
lymphocytic choriomeningitis virus. Infect. Immun. 10: 516-519. 
 
Welsh, R.M. and Selin, L.K. 2002. No One is Naïve: the significance of heterologous T-
cell immunity. Nature Rev. 2: 417-426. 
 
Yewdell, J.W. and Bennink, J.R. 1999. Immunodominance in major histocompatibility 
complex class I-restricted T lymphocyte responses. Annu. Rev. Immunol. 17: 51-88. 
